PenderFund Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

PenderFund Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-16,480	Closed	-$839K	–	142
2023 Q2	$839K	Buy	+16,480	New	+$423K	0.26%	62

PenderFund Capital Management's KDNY Position: Q3 2023 in Review

PenderFund Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 16,480 shares — an estimated $839K sold.

PenderFund Capital Management first reported a position in KDNY in Q2 2023 and held it in 1 quarter. The position peaked at $839K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

PenderFund Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
PenderFund Capital Management sold 16,480 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $839K.
PenderFund Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
PenderFund Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $839K in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on PenderFund Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.